| |
|
|
Bukwang Pharmaceutical (003000) |
|
|
STOCK |
|
|
| Address |
398-1,DAEBANG-DONG, DONGJAK-GU, SEOUL |
| Home Page |
www.bukwang.co.kr
|
| Established |
1960.10.17 |
Tel |
02-828-8114 |
| Listed |
1988. 8. 5 |
IR |
02-828-8034 |
| Common shares O/S |
27,045,225 |
President |
Lee,Seong Gu |
| Preferred shares O/S |
|
No.of Employees |
543(2008. 3) |
| Sales increased on expectations that its type B hepatitis drug will gain strong popularity. Its profitability improved sharply on increased sales and reduced costs. Its sales are expected to post a steady growth on the back of its Hepatitis B drug despite a fall in sales of other generic medicines. |
| Its profitability is forecast to improve on strong sales of its Hepatitis B drug. Overseas sales are also expected to increase, led by sales of Hepatitis B drug. The company is expected to gain from its affiliate Antrogen, which produces stem cell-related drugs. |
|
  |
(date: 2007.12, unit : %) |
| Name |
Kim Dongyeon |
Jeong Changsu |
Kim Gihwan |
| Portion |
25.1 |
11.8 |
5.5 |
|
 |
(unit : %) |
| Sales |
Thioctacid |
15.4 |
Cost |
Raw Materials |
|
| Lagalon Susp |
11.5 |
Labors |
|
|
|
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
98. 7 |
99. 6 |
00. 6 |
04.10 |
07. 6 |
| Type |
SS |
SD |
SD |
BI |
SD |
| Amount |
500.00 |
9.72 |
5.14 |
10.80 |
5.93 |
|
|
|
|
